RNA-seq and integrated network analysis reveals the hub genes and key pathway of paclitaxel inhibition on Adriamycin resistant diffuse large B cell lymphoma cells

References

• Bucher P, Erdmann T, Grondona P, et al. Targeting chronic NFAT activation with calcineurin inhibitors in diffuse large B-cell lymphoma. Blood. 2020;135(2):121–132.
   PubMed Web of Science ®Google Scholar
• Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679–690.
   PubMed Web of Science ®Google Scholar
• Hartert KT, Wenzl K, Krull JE, et al. Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL. Leukemia. 2021;35(2):522–533.
   PubMed Web of Science ®Google Scholar
• Fisher RI. Treatment of diffuse large B-cell lymphomas. Semin Hematol. 2006;43(4):205–206.
   PubMed Web of Science ®Google Scholar
• Mondello P, Mian M. Frontline treatment of diffuse large B-cell lymphoma: beyond R-CHOP. Hematol Oncol. 2019;37(4):333–344.
   PubMed Web of Science ®Google Scholar
• Wilson WH. Drug resistance in diffuse large B-cell lymphoma. Semin Hematol. 2006;43(4):230–239.
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Van Den Neste E. How I manage patients with relapsed/refractory diffuse large B cell lymphoma. Br J Haematol. 2018;182(5):633–643.
   PubMed Web of Science ®Google Scholar
• Lesokhin AM, Ansell SM, Armand P, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol. 2016;34(23):2698–2704.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Ribrag V, Moskowitz CH, et al. Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma. Blood. 2017;130(3):267–270.
   PubMed Web of Science ®Google Scholar
• Luo Q, Pan W, Zhou S, et al. A novel BCL-2 inhibitor APG-2575 exerts synthetic lethality with BTK or MDM2-p53 Inhibitor in diffuse large B-cell lymphoma. Oncol Res. 2020;28(4):331–344.
   PubMed Web of Science ®Google Scholar
• Kumari P, Dang S. Anti-cancer potential of some commonly used drugs. Curr Pharm Des. 2021;27(45):4530–4538.
   PubMed Web of Science ®Google Scholar
• Alqahtani FY, Aleanizy FS, Tahir EE, et al. Paclitaxel Profiles Drug Subst Excip Relat Methodol . 2019;44:205–238.
   PubMedGoogle Scholar
• Nightingale SL. From the food and drug administration. Jama. 1992;268(11):1390.
   PubMedGoogle Scholar
• Mekhail TM, Markman M. Paclitaxel in cancer therapy. Expert Opin Pharmacother. 2002;3(6):755–766.
   PubMedGoogle Scholar
• Zhu L, Chen L. Progress in research on paclitaxel and tumor immunotherapy. Cell Mol Biol Lett. 2019;24:40.
   PubMed Web of Science ®Google Scholar
• Rizzieri DA, Sand GJ, McGaughey D, et al. Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma. Cancer. 2004;100(11):2408–2414.
   PubMed Web of Science ®Google Scholar
• Westin JR, McLaughlin P, Romaguera J, et al. Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 2014;167(2):177–184.
   PubMed Web of Science ®Google Scholar
• Wu L, Wang J, Li Y, et al. Development of taxane-containing chemotherapy of doxorubicin-resistant diffuse large B-cell lymphoma. Anticancer Drugs. 2014;25(7):826–831.
   PubMed Web of Science ®Google Scholar
• Havas AP, Rodrigues KB, Bhakta A, et al. Belinostat and vincristine demonstrate mutually synergistic cytotoxicity associated with mitotic arrest and inhibition of polyploidy in a preclinical model of aggressive diffuse large B cell lymphoma. Cancer Biol Ther. 2016;17(12):1240–1252.
   PubMed Web of Science ®Google Scholar
• Luo B, Gu -Y-Y, Wang X-D, et al. Identification of potential drugs for diffuse large b-cell lymphoma based on bioinformatics and connectivity map database. Pathol Res Pract. 2018;214(11):1854–1867.
   PubMed Web of Science ®Google Scholar
• Huang Yun SJ, Qing K, Biqi L, et al. Establishment of adriamycin-resistant human diffuse large B-cell lymphoma cell lines and study on its characteristics Journal of Guangxi Medical University . Journal of GuangXi Medical University. 2017;34(3):332–337.
   Google Scholar
• Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000;25(1):25–29.
   PubMed Web of Science ®Google Scholar
• Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27–30.
   PubMed Web of Science ®Google Scholar
• von Mering C, Huynen M, Jaeggi D, et al. STRING: a database of predicted functional associations between proteins. Nucleic Acids Res. 2003;31(1):258–261.
   PubMed Web of Science ®Google Scholar
• Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–2504.
   PubMed Web of Science ®Google Scholar
• Bader GD, Hogue CW. An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinformatics. 2003;4:2.
   PubMed Web of Science ®Google Scholar
• Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–404.
   PubMed Web of Science ®Google Scholar
• Tang Z, Kang B, Li C, et al. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47(W1):W556–w560.
   PubMed Web of Science ®Google Scholar
• Thul PJ, Lindskog C. The human protein atlas: a spatial map of the human proteome. Protein Sci. 2018;27(1):233–244.
   PubMed Web of Science ®Google Scholar
• Sherry ST, Ward MH, Kholodov M, et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 2001;29(1):308–311.
   PubMed Web of Science ®Google Scholar
• Bowen RC, Hahn AW, Butler TW, et al. Complete response to azacitidine priming and nab-paclitaxel in non-Hodgkin lymphoma resistant to biochemotherapy. Mol Clin Oncol. 2017;6(1):122–124.
   PubMed Web of Science ®Google Scholar
• Gu C, Yang H, Chang K, et al. Melatonin alleviates progression of uterine endometrial cancer by suppressing estrogen/ubiquitin C/SDHB-mediated succinate accumulation. Cancer Lett. 2020;476:34–47.
   PubMed Web of Science ®Google Scholar
• Scarpa ES, Tasini F, Crinelli R, et al. The ubiquitin gene expression pattern and sensitivity to UBB and UBC knockdown differentiate primary 23132/87 and metastatic MKN45 gastric cancer cells. Int J Mol Sci. 2020;21(15). DOI:10.3390/ijms21155435.
   Web of Science ®Google Scholar
• Chu SH, Liu Y-W, Zhang L, et al. Regulation of survival and chemoresistance by HSP90AA1 in ovarian cancer SKOV3 cells. Mol Biol Rep. 2013;40(1):1–6.
   PubMed Web of Science ®Google Scholar
• Xiao X, Wang W, Li Y, et al. HSP90AA1-mediated autophagy promotes drug resistance in osteosarcoma. J Exp Clin Cancer Res. 2018;37(1):201.
   PubMedGoogle Scholar
• Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkitt’s lymphoma. N Engl J Med. 2006;354(23):2431–2442.
   PubMed Web of Science ®Google Scholar
• Goy A, Stewart J, Barkoh BA, et al. The feasibility of gene expression profiling generated in fine-needle aspiration specimens from patients with follicular lymphoma and diffuse large B-cell lymphoma. Cancer. 2006;108(1):10–20.
   PubMed Web of Science ®Google Scholar
• Vallat LD, Park Y, Li C, et al. Temporal genetic program following B-cell receptor cross-linking: altered balance between proliferation and death in healthy and malignant B cells. Blood. 2007;109(9):3989–3997.
   PubMed Web of Science ®Google Scholar
• Grade M, Hummon AB, Camps J, et al. A genomic strategy for the functional validation of colorectal cancer genes identifies potential therapeutic targets. Int J Cancer. 2011;128(5):1069–1079.
   PubMed Web of Science ®Google Scholar
• Ali M, Ajore R, Wihlborg A-K, et al. The multiple myeloma risk allele at 5q15 lowers ELL2 expression and increases ribosomal gene expression. Nat Commun. 2018;9(1):1649.
   PubMedGoogle Scholar
• Catez F, Dalla Venezia N, Marcel V, et al. Ribosome biogenesis: an emerging druggable pathway for cancer therapeutics. Biochem Pharmacol. 2019;159:74–81.
   PubMed Web of Science ®Google Scholar
• Marcel V, Catez F, Berger CM, et al. Expression Profiling Of Ribosome Biogenesis Factors Reveals Nucleolin As A Novel Potential Marker To Predict Outcome in AML patients. PLoS One. 2017;12(1):e0170160.
   PubMed Web of Science ®Google Scholar
• El Hassouni B, Sarkisjan D, Chris Vos J, et al. Targeting the ribosome biogenesis key molecule fibrillarin to avoid chemoresistance. Curr Med Chem. 2019;26(33):6020–6032.
   PubMed Web of Science ®Google Scholar
• Linschoten M, Kamphuis JAM, van Rhenen A, et al. Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis. Lancet Haematol. 2020;7(4):e295–e308.
   PubMed Web of Science ®Google Scholar
• Kong X, Kuilman T, Shahrabi A, et al. Cancer drug addiction is relayed by an ERK2-dependent phenotype switch. Nature. 2017;550(7675):270–274.
   PubMed Web of Science ®Google Scholar